Key result
Omecamtiv mecarbil induces an ~11° lever rotation and primes phosphate release in cardiac myosin.
Why the study?
Omecamtiv mecarbil prevents the force-generating lever swing of myosin while accelerating inorganic phosphate release, but the structural basis by which it accelerates phosphate release remained poorly understood.
Cryo-EM structural analysis reveals that omecamtiv mecarbil remodels the nucleotide-binding site of human β-cardiac myosin to shift inorganic phosphate toward its exit pathway, explaining how it accelerates the weak-to-strong actomyosin-binding transition.
Answers are grounded in this paper and cite their sources.
Atomic details of OM-myosin interaction extend kinetic models; leaves clinical use in systolic HF open.
Omecamtiv mecarbil (OM) was considered to be a cardiac muscle activator in clinical trials for alleviation of systolic heart failure. Yet, it was later shown to be a potent inhibitor of myosin motor activity. Its binding to myosin prevents the force-generating lever swing but also accelerates the release of inorganic phosphate (P i ), such that in muscle OM enhances overall force production by cooperatively increasing the number of actomyosin cross-bridges. The structural basis by which it accelerates P i release remains poorly understood. Here, using cryogenic electron microscopy, we determined the structure of the human β-cardiac myosin motor domain in the presence of MgATP and OM to 3.2 Å global resolution. The structure adopts a primed state with well resolved OM density within its established binding pocket, and density within the active site consistent with a post-hydrolysis MgADP·P i state. OM stabilizes interactions bridging the converter and N-terminal subdomains of the myosin motor, inducing a 11° lever rotation and altering relay-helix conformation relative to the drug-free motor to prevent the force-generating lever swing. Comparison of this structure with that of bovine cardiac myosin with OM and MgADP·vanadate bound, determined by crystallography, revealed subtle but meaningful differences. OM remodels the nucleotide-binding site, shifting the P i density ∼2 Å towards its proposed exit pathway. This altered P i coordination provides a plausible structural rationale for a mechanism by which OM accelerates the weak-to-strong actomyosin-binding transition, key to its therapeutic function. By stabilizing a conformation in which P i is not coordinated to MgADP, P i is likely freely released upon opening of its exit pathway. This structural observation is also consistent with previous kinetic studies that showed that OM shifts the equilibrium constant for ATP hydrolysis towards the post-hydrolysis state. This mechanistic understanding will be beneficial to the development of more effective myosin-targeting therapeutics.
No takes yet. Share an insight, caveat, or question.
McMillan et al. (2026) studied Systolic heart failure. Omecamtiv mecarbil vs. Drug-free motor and bovine cardiac myosin with OM and MgADP·vanadate bound was evaluated on Cryo-EM structural determination of the human β-cardiac myosin motor domain. Omecamtiv mecarbil induced an 11° lever rotation and shifted inorganic phosphate density ~2 Å toward its exit pathway in the human β-cardiac myosin motor domain.
Synapse has enriched 10 related papers. Consider them for comparative context: